- The company enjoys strong secular tailwinds from a growing regenerative medicine market, gaining lots of new customers and seeing existing customers move through clinical phases.
- Acquisitions have added significantly to the TAM and provided multiple leverage opportunities, especially in sales.
- Gross margins have taken a hit from the acquisitions and dilution has been substantial.
- While the shares are fully valued at the moment, the company appears to be an unstoppable juggernaut.
For further details see:
BioLife Solutions: The Whole Is Much More Than The Sum Of The Parts